| Today’s Big NewsMay 2, 2024 |
|
Therapeutic RNAs offer several advantages over other therapies due to their specificity and versatility, leading researchers to make great strides towards personalized medicine. Download the QPS white paper for insights into the future of RNA Therapies. 
|
|
| By Annalee Armstrong With much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep dive into the unknown with Mariana Oncology in a $1 billion upfront acquisition. |
|
|
|
By Kevin Dunleavy Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat COPD could be delayed, as the FDA has requested additional efficacy data from two trials. The regulatory hurdle comes as Eylea showed stagnant sales, even though its new high-dose formula is seeing increased uptake. |
By Conor Hale The U.S. Preventive Services Task Force officially updated its recommendations this week for who should be screened for breast cancer and when, but did not go as far some had hoped. |
By Andrea Park With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist market and help pharma and biotech teams prepare for future market moves “with the speed and agility they need,” according to the healthcare agency’s Rita Glaze-Rowe. |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now. 
|
|
By Zoey Becker Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug. |
By Max Bayer Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter of weeks. But clinical investments are also pouring into a late-stage cancer treatment. |
By Gabrielle Masson Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks. |
By Conor Hale The deal includes the company’s Microtek lines of sterile drapes for covering patients and OR equipment, as well as Ecolab’s fluid temperature management system. Medline said the purchase will also expand its design and development capabilities in original equipment manufacturing. |
By Angus Liu AstraZeneca is touting a earlier-than-expected positive readout for Calquence in first-line mantle cell lymphoma. But a big question remains whether it can immediately file with the FDA, especially given the precedent of Imbruvica. |
By Annalee Armstrong The next frontier for pharma in the obesity space is improving the quality of that weight loss. As potential combo drugs inch closer to phase 3, what exactly will the FDA be looking for in terms of a clinical endpoint? |
By Andrea Park In the face of daunting statistics about the sometimes-fatal effects of preeclampsia, Mirvie is helping lead the charge to educate people about how the pregnancy complication can be prevented. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Fierce Healthcare Senior Writer Anastassia Gliadkovskaya dives into the details of the innovation hub being built in New Jersey's SciTech City. |
|
|---|
|
|
|
Wednesday, May 22, 2024 | 11am ET / 8 am PT Learn GMP regulations in pharmaceutical storage at our upcoming webinar. Discover FDA requirements, including space validation, environmental controls, and risk mitigation. Explore services like aliquoting and cold chain transportation. Register now. 
|
|
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
